Arena And Vivus Take Divergent Paths To Respond To Obesity Setbacks

To little surprise, FDA has issued “complete responses” for two of the main competitors racing to develop new obesity drugs. While both drug candidates were knocked down on their first pass over by the agency, the similarities stop there.